Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD20 + status confers therapeutic sensitivity to Cyclophosphamide, Doxorubicin, Etoposide, Prednisolone, Rituximab, Vincristine in patients with Non-Hodgkin Lymphoma.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of patients with CD20 positive diffuse large B-cell Non Hodgkin's lymphoma (NHL).